Gracell Biotechnologies Inc. (GRCL) News

Gracell Biotechnologies Inc. (GRCL): $3.29

-0.04 (-1.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GRCL to Watchlist
Sign Up

Industry: Beverages


Ranked

of 35

in industry

Filter GRCL News Items

GRCL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GRCL News Highlights

  • GRCL's 30 day story count now stands at 4.
  • Over the past 19 days, the trend for GRCL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about GRCL are ALTO.

Latest GRCL News From Around the Web

Below are the latest news stories about Gracell Biotechnologies Inc that investors may wish to consider to help them evaluate GRCL as an investment opportunity.

Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform

Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced multiple advancements of its TruUCAR platform, the Company's proprietary technology platform designed to generate high-quality allogeneic CAR-T cell therapies that can be administered "off-the-shelf" as stand-alone therapy at lower cost and with greater conve

Yahoo | February 22, 2022

Week In Review: China's NMPA Approves Pfizer's Oral COVID-19 Therapy Paxlovid

Deals and Financings Shanghai AffaMed recently in-licensed ex-Asia (plus Japan) rights to a novel bispecific biologic molecule aimed at retinal vascular diseases from AskGene Pharma of Southern California. Today, AffaMed announced US approval to start clinical trials of the candidate, AM712, a dual inhibitor of vascular endothelial growth factor (VEGF)...

ChinaBio Today on Seeking Alpha | February 21, 2022

Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma

Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has dosed multiple patients in a clinical trial evaluating GC012F, the Company's autologous CAR-T therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19 in B-cell non-Hodgkin's lymphoma (B-NHL). NHL is the fifth most common can

Yahoo | February 17, 2022

Gracell Biotechnologies to Participate in Citi 2022 Virtual Immuno-Oncology Summit

SUZHOU, China and PALO ALTO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Citi 2022 Immuno-Oncology Summit on February 16th. Dr. William Cao, Founder, Chairman and CEO of Gracell will participate in a fireside cha

Yahoo | February 3, 2022

Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference

SUZHOU, China and PALO ALTO, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the B Riley Securities 2022 Virtual Oncology Conference from January 27th to 28th. The Gracell team is scheduled to have a presentation at 2:30

Yahoo | January 18, 2022

Gracell Biotechnologies Unveils Innovation Center in U.S.

Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its newly established research facility, the Innovation Center, is scheduled to open in San Diego, California, during the first quarter of 2022.

Yahoo | January 12, 2022

Federated Hermes Prudent Bear Fund Buys PowerShares QQQ Trust Ser 1, iShares Russell 2000 ETF, ...

Investment company Federated Hermes Prudent Bear Fund (Current Portfolio) buys PowerShares QQQ Trust Ser 1, iShares Russell 2000 ETF, iShares MSCI Emerging Markets ETF, SPDR Biotech ETF, iShares MSCI EAFE ETF, sells S&P 500 ETF TRUST ETF, Financial Select Sector SPDR, Health Care Select Sector SPDR, ARK Genomic Revolution ETF, Cisco Systems Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Federated Hermes Prudent Bear Fund.

Yahoo | December 25, 2021

Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index

Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). Addition to the NBI will become effective prior to market open on Monday, December 20, 2021.

Yahoo | December 16, 2021

Gracell Biotechnologies (GRCL) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | December 13, 2021

Gracell Biotechnologies (NASDAQ:GRCL) Shares Up 4.1%

Gracell Biotechnologies Inc. (NASDAQ:GRCL)s share price shot up 4.1% during mid-day trading on Tuesday . The stock traded as high as $7.62 and last traded at $7.55. 11,899 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,232,226 shares. The stock had previously closed at $7.25. Separately, Zacks []

Transcript Daily | December 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5372 seconds.